BMS-986188（Cat No.:R066989）is a selective small molecule inhibitor targeting the protein PD-1 (programmed cell death protein 1) on immune cells. PD-1 plays a significant role in suppressing immune responses by interacting with its ligands, PD-L1 and PD-L2, which are often upregulated in tumors to evade immune detection. By inhibiting PD-1, BMS-986188 enhances T-cell activation and promotes an immune response against cancer cells. Preclinical and early clinical studies suggest its potential as an immunotherapeutic agent in cancer treatment, particularly in combination with other immune checkpoint inhibitors for enhanced anti-tumor efficacy.